{"url_path":"/sec/halo/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000068-index.html","accession_number":"0001159036-26-000068","cik":"0001159036","ticker":"HALO","issuer_name":"HALOZYME THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000068-index.html","primary_entity_key":"0001159036","primary_entity_name":"HALOZYME THERAPEUTICS, INC."},"word_count":605,"has_tables":true,"body_markdown":"Item 6.Exhibits\n\n3.1\n[Amended and Restated Certificate of Incorporation of Halozyme Therapeutics, Inc. (filed as Exhibit 3.1 to the Company’s Form 8-K filed April 26, 2024 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/exhibit31amendedandrestate.htm)\n\n3.2\n[The Company Bylaws, as amended (filed as Exhibit 3.1 to the Company’s Form 8-K filed April 24, 2026 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000051/ex31halozyme-amendedandres.htm)\n\n4.1\n[Indenture, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (](http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm)[filed as Exhibit 4.1 to the Company’s Form 8-K filed March 1, 2021 and incorporated herein by reference](http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm)[)](https://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm)\n\n4.2\n[Form of Note, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (](http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm)[filed as Exhibit 4.2 to the Company’s Form 8-K filed March 1, 2021 and incorporated herein by reference](http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm)[)](https://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm)\n\n4.3\n[Indenture, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (](http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm)[filed as Exhibit 4.1 to the Company’s Form 8-K filed August 18, 2022 and incorporated herein by reference](http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm)[)](https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm)\n\n4.4\n[Form of Note, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (included within Exhibit 4.3) (](http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm)[filed as Exhibit 4.2 to the Company’s Form 8-K filed August 18, 2022 and incorporated herein by reference](http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm)[)](https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm)\n\n4.5\n[2031 Convertible Notes](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[I](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[ndenture, dated November 12, 2025, between Halozyme Ther](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[apeutics, Inc. and The Bank of New York Mellon Trust Company](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[, N.A., as tr](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[ustee (filed as Exhibit 4.1](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[to the Company](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[’](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[s Form 8-K filed November 12, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)\n\n4.6\n[F](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[orm of 0% Convertible](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[Senior Notes due 2031 (included with](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[in Exhibit 4.5) (filed as Exhibit 4.2 to the C](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[ompany](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[’](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[s Form 8-K filed November 12, 2025 and incorporated herein by ref](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)[erence)](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex41.htm)\n\n4.7\n[203](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[2](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[Convertible Notes Indenture, dated November 12, 2025, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[3](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)\n\n4.8\n[Form of 0](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[.875](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[% Convertible Senior Notes due 203](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[2](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[(included within Exhibit 4.](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[7](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[) (filed as Exhibit 4.](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[4](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)[to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920dex43.htm)\n\n31.1\n[Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended](ex31110qq12026.htm) (filed herewith)\n\n31.2\n[Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended](ex31210qq12026.htm) (filed herewith)\n\n32\n[Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex3210qq12026.htm) (furnished herewith)\n\n101.INSInstance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document (filed herewith)\n\n101.SCHInline Taxonomy Extension Schema Document (filed herewith)\n\n101.CALInline Taxonomy Extension Calculation Linkbase Document (filed herewith)\n\n101.DEFInline Taxonomy Extension Definition Linkbase Document (filed herewith)\n\n101.LABInline Taxonomy Extension Label Linkbase Document (filed herewith)\n\n101.PREInline Taxonomy Extension Presentation Linkbase Document (filed herewith)\n\n104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (filed herewith)\n\n66\n\n[Table of Contents](#i66ba8166e9c94bfbbdc8e24cab8d4507_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. \n\n \nHalozyme Therapeutics, Inc.\n\n(Registrant)\n\n \n\nDated: May 11, 2026\nBy:\n/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.\n\n Helen I. Torley, M.B. Ch.B., M.R.C.P.\nPresident and Chief Executive Officer\n(Principal Executive Officer)\n\n \n\n \n\nDated:May 11, 2026\nBy:\n\n/s/ David Ramsay\n\n \nDavid Ramsay\n\nInterim Chief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n67"}